Cart
sales@molnova.com
Tulmimetostat
CAS No. 2567686-02-4
Tulmimetostat( —— )
Catalog No. M35187 CAS No. 2567686-02-4
Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 60 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 183 | In Stock |
|
| 50MG | 269 | In Stock |
|
| 100MG | 532 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTulmimetostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionTulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.
-
DescriptionTulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor. Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorHistone Methyltransferase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2567686-02-4
-
Formula Weight562.12
-
Molecular FormulaC28H36ClN3O5S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C2C(O[C@@](C)(O2)[C@@]3(CC[C@H](CC3)N4CC(OC)C4)[H])=C(Cl)C=C1C(NCC5=C(SC)C=C(C)NC5=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.
molnova catalog
related products
-
Boc-(Asp(OBzl)16)-Ga...
Boc-(Asp(OBzl)16)-Gastrin I (13-17) (human)
-
Ornidazole
Ornidazole(Ro 7-0207) is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria.
-
8-Prenylkaempferol
8-Prenylkaempferol is an effective agent for attenuating pro-inflammatory NO induction, it may be an anti-inflammatory agent for suppressing influenza A virus-induced RANTES production acts by blocking PI3K-mediated transcriptional activation of NF-κB and IRF-3 and in part by interfering with IκB degradation which subsequently decreases NF-κB translocation.
